Andrea Hunklinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Hunklinger has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Merk
Department of Pharmacy Ludwig‐Maximilians‐Universität München Munich Germany
1 shared publication Domenic Mayer
Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication- Max Lewandowski
Ludwig-Maximilians-Universität München
1 shared publication - Noelia Ferruz
Centre for Genomic Regulation
1 shared publication - Thomas Wein
Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication - Tim Hörmann
Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication
Latest Publications
- 11 May 2026
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 8 (5) , 649-662
Towards the explainability of protein language models
- 11 May 2026
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 8 (5) , 649-662
Towards the explainability of protein language models
- Open Access
- 11 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structural optimization of drug molecules with incrementally trained language models
Automating structural optimization of drug molecules for on-target potency by machine learning is an open challenge in chemistry. Here, we capitalize on the ability of chemical language models (CLMs) to learn from sequential data and design new molecules with desired properties. We establish a training strategy mimicking the learning trajectory of a drug discovery program. Incremental CLM fine-tuning with increasingly potent template molecules from a given structure-activity relationship (SAR) series successfully biases the model to design highly active analogues. Prospective application of this technique to ligand development enables the data-driven design of molecules exceeding known representatives of given bioactive chemotypes in potency without external scoring. Our results reveal an ability of CLMs to capture SAR patterns and long-range dependencies, and to exploit SAR knowledge in designing analogues with improved on-target activity de novo corroborating their applicability to structural optimization of drug molecules.
- 11 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessStructural optimization of drug molecules with incrementally trained language models
Automating structural optimization of drug molecules for on-target potency by machine learning is an open challenge in chemistry. Here, we capitalize on the ability of chemical language models (CLMs) to learn from sequential data and design new molecules with desired properties. We establish a training strategy mimicking the learning trajectory of a drug discovery program. Incremental CLM fine-tuning with increasingly potent template molecules from a given structure-activity relationship (SAR) series successfully biases the model to design highly active analogues. Prospective application of this technique to ligand development enables the data-driven design of molecules exceeding known representatives of given bioactive chemotypes in potency without external scoring. Our results reveal an ability of CLMs to capture SAR patterns and long-range dependencies, and to exploit SAR knowledge in designing analogues with improved on-target activity de novo corroborating their applicability to structural optimization of drug molecules.